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A methanolic extract of Harpagophytum procumbens as well as harpagoside and harpagide were tested 
as direct inhibitors of cyclooxygenase-2 enzyme (COX-2). The H. procumbens extract demonstrated 
direct inhibition (68%) of COX-2 enzyme. The concentration of harpagoside and harpagide equivalent to 
that found in the extract (3 and 1% respectively) contributed 1.5 and 13% to this inhibition. Results 
indicated direct COX-2 enzyme inhibition by the H. procumbens extract due to possible synergistic 
activity of active components in the extract, which include harpagide and harpagoside. 
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INTRODUCTION 
 
Devil’s claw (Harpagophytum procumbens) is a plant 
geographically located in many regions throughout 
Southern Africa. It’s typical habitat is open savannahs 
and arid regions. The plant root has been used for the 
treatment of osteoarthritic conditions and has analgesic 
properties (Van Wyk et al., 1997). Devil’s claw contains 
iridiode glycosides, sugars, triterpenes, sterols and fats 
(Wichtl, 2004). The iridiode glycosides (harpagoside and 
harpagide) are believed to have medicinal properties 
(Van Wyk et al., 1997). 
H. procumbens extract and its various active 
components have anti-inflammatory properties expressed 
by different mechanisms of activity (Fiebich et al., 2001; 
Loew et al., 2001; Benito et al., 2000). The clinical effica-
cy of H. procumbens for inflammatory conditions has 
been reported (Chrubasik et al., 2002). These reveal 
favourable results for the relief of osteoarthritic conditions 
with H. procumbens and harpagoside as compared to 
anti-arthritic drugs, refecoxib and diacerein (Gagnier et 
al., 2004; Chantre et al., 2000). Questions have been 
raised about the clinical assessment criteria used in some 
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studies (McGregor et al., 2005). 
  Studies involving COX-2 inhibition by H. procumbens 
extract in animals indicate significant reduction in pain 
and inflammation induced by experimental test proce-
dures. These include Freund's adjuvant induced arthritis 
and carrageenan-induced rat paw oedema (Anderson et 
al., 2004; Lanhers et al., 1992). However, animal studies 
tend to indicate that isolated components, such as 
harpagoside do not demonstrate anti-inflammatory pro-
perties (McGregor et al., 2005; Lanhers et al., 1992). 
Two forms of cyclooxygenase are known, namely, 
cyclooxygenase-1 (COX-1) and cylclooxygenase-2 
(COX-2). COX-1 is a constitutive enzyme and COX-2 is 
induced in inflammatory cells by inflammatory stimuli 
(Rang et al., 2003). Anti-inflammatory properties of H. 
procumbens extract and its active components have 
been attributed to the inhibition of activities related to the 
pathways of COX-1 (Jang et al., 2003) and COX-2 
(Abdelouahab and Heard, 2008), the latter being more 
frequently investigated. 
Cyclooxygenase enzyme inhibition studies may be 
categorized by (a) measuring direct inhibition of enzyme 
activity by the inhibitor; (b) measuring the inhibition of 
enzyme activity through reduced enzyme expression; or 
(c) measuring other biochemical activities due to reduced 
enzyme output. The last two are  categorized  as  indirect 
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measurements of inhibition as demonstrated by 
McGregor et al. (2005) and Kundu et al. (2005) with the 
H. procumbens extract, respectively. 
In vitro studies investigating constituents of H. 
procumbens extract, such as harpagoside and harpagide 
reveal opposing results in its ability to inhibit COX-2 
activity (Abdelouahab and Heard, 2008; Fiebich et al., 
2001). This may be related to differences in the method 
of inhibition assessment and plant extract composition 
(McGregor et al., 2005; Loew et al., 2001). The H. 
procumbens extract with all its constituents seem to be 
the most effective in the inhibition of COX-2 as compared 
to its individual constituents, which may be related to 
synergy (Abdelouahab and Heard, 2008). 
Synergistic interactions of compounds may play an 
important role in improved therapeutic activity of medici-
nal plants. In addition, crude extracts may also offer 
better stability of various active compounds and may in-
clude the presence of unknown constituents (Williamson, 
2001).  
The present study demonstrates direct inhibition of 
COX-2 enzyme (in contrast to others which focus on 
indirect inhibition) by an extract of H. procumbens as well 
as pure harpagoside and harpagide. DuP-697 [5-bromo-
2-(4-flourophenyl)-3-(4-(methylsulfonyl)-thiophene)], a 
member of the diaryl heterocyclic group of selective 
COX-2 inhibitors, which includes MK-966 recoxib and 
celocoxib, was used as the reference inhibitor. Copeland 
et al. (1994) demonstrated significant direct COX-2 
enzyme inhibition by DuP-697. 
Harpagoside was identified in the H. procumbens 
extract by thin layer chromatography (TLC) and after puri-
fication by UV-spectroscopy. Harpagide was identified in 
the extract by TLC after spraying with a visualization 
reagent. Weak UV absorption characteristics of harpa 
gide rendered confirmative UV spectroscopy unfeasible. 
Quantification of both compounds was done by quantita- 
tive TLC. 
 
 
METHODOLOGY 
 
Preparation of H. procumbens extract 
 
Dried H. procumbens (A. White Chemist, South Africa) was 
powdered using a hammer mill (Cullati, Germany). Methanol 
(Sigma-Aldrich, South Africa) was added to a final powder 
concentration of 100 mg/ml. The samples were vortexed for 5 min 
followed by shaking at 400 rpm (Infors HT, Switzerland) for 5 min at 
room temperature. Thereafter, it was centrifuged at 8000 rpm for 5 
min (Hëttich, Germany) and the methanol phase was carefully 
removed from the pellet. This supernatant was concentrated by the 
removal of the methanol at 35°C under a gentle stream  of nitrogen 
resulting in a resinous H. procumbens extract which was stored (-
20°C). 
 
 
Identification of the extract components 
 
Thin layer chromatography  analysis  was  performed  on  methanol 
 
 
 
 
reconstituted solutions of the resinous crude extract (400 mg/ml) 
with a mobile phase of butanol (Merck, South Africa), acetic acid 
(Merck, South Africa) and water (12:3:5). Five microlitres of the 
sample was applied to the TLC plates (silica gel 60, F254, Merck, 
South Africa) and chromatographed over a plate length of 8 cm with 
pure harpagoside and harpagide (PhytoPlan, Germany) in 
methanol as reference chemical standards. The TLC plates were air 
dried, observed under UV light (254 nm), compounds marked, and 
they were sprayed with a solution containing 1% (w/v) vanillin 
(Sigma-Aldrich, South Africa) in ethanolic sulfuric acid, by means of 
an aerosol spraying device. It was then heated (5 min, 80°C) in an 
oven yielding identifiable visible spots. The chromatographed 
compounds on the plate were quantified using a scanner connected 
to a laptop computer with specialized Quantiscan software version 
3 (Biosoft, England) with the ability to quantify and differentiate 
between chromatographed compounds. 
In order to perform confirmative UV-spectroscopy (Cintra 202, 
Australia) on the chromatographed harpagoside, further purification 
was necessary. This was achieved by following preparative TLC 
methods under the same conditions. Chromatographed 
harpagoside bands on the TLC plates were removed from the 
plates, extracted with methanol and the UV spectrum of the TLC 
purified harpagoside was determined by UV spectroscopy in 
phosphate buffered saline solution. 
 
 
Determination of cyclooxygenase- 2 inhibition 
 
COX-2 inhibition experiments were based on the methods reported 
by Copeland et al. (1994) and Corazzi et al. (2005) with minor 
changes. Twenty-five units of purified COX-2 (ovine) enzyme 
(Cayman Chemical, USA) were added to 700 µl of enzyme 
reaction buffer. The buffer consisted of 100 mM sodium phosphate 
pH 6.5, 0.5 µM hematin (Sigma-Aldrich, South Africa) and 1 mg/ml 
gelatin (Sigma-Aldrich, South Africa). The enzymatic reaction was 
initiated by adding 100 µM of arachadonic acid (Sigma-Aldrich, 
South Africa) and 50 µM N,N,N’,N’-tetramethyl-p-phenylenediamine 
(TMPD) (Sigma-Aldrich, South Africa) to a final reaction mixture of 1 
ml. 
Various concentrations of COX-2 inhibitors, namely; H. 
procumbens extract, harpagoside and harpagide were dissolved in 
dimethsulphoxide (DMSO) (Merck, South Africa) and added to the 
reaction solution buffer 15 min before arachadonic acid and TMPD 
were added.  DuP-697 was dissolved in dimethylformamide (Merck, 
South Africa) instead of DMSO. All determinations were performed 
in triplicate. 
COX-2 activity was determined by measuring UV absorption 
change of the reaction mixture at wavelength 610 nm exactly 8 min 
after initiating the reaction against the appropriate blank. No change 
of initial absorption values indicated 100% inhibition and maximum 
absorption change in the reaction without added inhibitors indicated 
zero inhibition. Data was fitted into GraphPad Prism version 5 
software for the calculation of mean, standard deviation (SD) and 
IC50 values. 
 
 
RESULTS AND DISCUSSION 
 
TLC of harpagoside present in the H. procumbens extract 
showed an Rf value of 0.68 when viewed under the UV 
light, which corresponded to the harpagoside standard. 
UV-spectrometry of the purified compound was identical 
to that of the harpagoside standard with the ratio of peak 
maxima to minima at wavelength 280 and 233 nm of 
1.87. TLC of harpagide present in the extract could not 
be visualized on the plates under UV light. It was however  
  
 
 
 
 
Figure 1. Quantitative thin layer chromatography of H. 
procumbens extract with harpagoside and harpagide 
reference standards. Harpagoside Rf 0.68; Harpagide Rf 
0.37; Mobile Phase: butanol, acetic acid and water (12:3:5). 
Harpagide spots appeared reddish upon spraying with 1% 
vanillin in ethanolic sulfuric acid spray reagent. 
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Figure 2. DuP-697 and H. procumbens extract COX-2 inhibition 
curves at various dilutions. 
 
 
 
identified after spraying the plate with the 1% vanillin in 
ethanolic sulfuric acid spray reagent. It yielded a reddish 
spot, which correlated in colour and Rf value (0.37) with 
the harpagide standard (Figure 1). The TLC plates 
containing the harpagoside and harpagide were quantita-
tively analyzed using the Biosoft® Quantiscan software 
as described by Nikolova et al., (2004). Bruneton (1999) 
reported the quantity of iridiode glycosides, which include 
harpagoside and harpagide, present in the crude extract 
of H. procumbens to be between 0.5 and 3%. 
Quantitative analyses of the compounds screened on the 
developed TLC plates showed that the tested H. 
procumbens extract contained 3%  harpagoside  and  1% 
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Figure 3. Direct inhibition (%) of COX-2 (25 units) activity by H. 
procumbens extract, harpagoside and harpagide. (n = 3; mean ± 
S.D.). 
 
 
 
harpagide. 
Figure 2 illustrates the comparison of COX-2 inhibition 
between DuP-697 and Harpagophytum procumbens 
extract at 10 fold dilutions, starting at 0.12 mg (98% 
inhibition) and 2 mg (80% inhibition) respectively.  In 
addition to the fact that the DuP-697 concentrations were 
17 times lower than that of the extract, it exerted a 
greater inhibitory effect (40%) at lower concentrations 
(1:1000 dilution) compared to the extract. This difference 
in inhibition decreases to less than 20% at higher extract 
concentrations (1:10 dilution). Compared to the DuP-697, 
the Harpagophytum procumbens extract inhibition curve 
indicated a non-linear COX-2 inhibition at high and low 
concentrations, which may be explained by possible 
synergistic activity of compounds in the extract.  
Under these experimental conditions, higher concen-
trations of Harpagophytum procumbens extract could not 
be tested because of solubility limitations of the extract in 
the reaction buffer. Figure 3 illustrates direct COX-2 inhi-
bition by H. procumbens extract as well as harpagoside 
and harpagide at 0.2 mg. This was the highest 
concentration at the linear part of the extract’s inhibition 
curve (Figure 2). At a concentration of 0.2 mg, H. 
procumbens extract showed direct enzyme inhibition of 
68.3%, harpagoside 5% and harpagide 60% (Figure 3). 
The inhibition activity of the crude extract is similar to the 
results obtained by Jang et al. (2003) and Kundu et al. 
(2005). Their studies evaluated indirect inhibitory activity 
through COX-2 expression. Abdelouahab and Heard 
(2008) reported that harpagoside had higher inhibitory 
activity than harpagide and that the latter increased COX- 
expression. 
When enzyme inhibition of harpagoside and harpagide 
were tested at 0.006 and 0.002 mg, respectively, which is 
the quantity that these compounds are represented in 0.2 
mg of the extract, only 1 and 9% direct inhibition were 
demonstrated, respectively. Fiebich et al. (2001) demons- 
trated a similar trend where no COX-2 inhibitory effects 
(TNFα synthase inhibition) by harpagoside and harpagide 
were observed at concentrations of up to 0.01 mg.  
The contrasting  COX-2 inhibitory activity reported  may be 
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Table 1. IC50 values of DuP-697, H. procumbens 
extract, harpagide and harpagoside as COX-2 
inhibitors. 
 
Compound IC50 (mg/ml) 
DuP-697 0.000134 
H. Procumbens extract 0.1046 
Harpagide 0.1186 
Harpagoside 104.1 
 
 
 
as a result of the total extract containing different 
fractions of components resulting in synergistic, compli-
mentary or antagonistic effects (Loew et al., 2001).  
The calculated IC50 values derived from inhibition 
studies of the inhibitors used are listed in Table 1. It 
confirms higher inhibition activity of harpagide than 
harpagoside as direct inhibitor but less than H. 
procumbens extract and DuP-697. Combined COX-2 
inhibition of harpagoside and harpagide at the quantities 
present in 0.2 mg extract was 10% as compared to 
68.3% in the H. procumbens extract. This greater COX-2 
direct inhibition exerted by the H. procumbens extract 
may be as a result of other compounds in the extract 
possibly with synergistic effects as compared to the 
combined inhibition of the harpagide and harpagoside. 
This effect was demonstrated in Fiebich et al (2001) 
study where the inhibition is attributed to H. procumbens 
extract and not to the individual components, such as the 
harpagoside. Abdelouahab and Heard (2008) also 
suggested that the inhibition of COX-2 expression could 
be attributed to interplay of the active compounds present 
in the H. procumbens extract. This phenomenon was 
described by Williamson (2001) with plant extracts 
Ginkgo biloba and Cannabis sativa. 
 
 
Conclusion 
 
H. procumbens extract produced direct inhibition of COX-
2 enzyme, but less than DuP-697. COX-2 inhibition by H. 
procumbens extract is greater than that of harpagoside 
and harpagide at the same concentrations. Harpagide 
has up to 12 times more inhibition activity as direct COX-
2 enzyme inhibitor than harpagoside. The calculated 
combined inhibition of harpagoside and harpagide at the 
concentrations as they appear in the extract is 10% as 
compared to 68% by the H. procumbens extract. 
However, the combination of these two components, with 
other compounds, which form part of the extract, has an 
even greater direct inhibition of COX-2 enzymes.This 
difference in COX-2 inhibition may be attributed to 
interplay expressed by other components in the extract. 
  Future studies could combine the direct and indirect 
mechanisms of COX-2 inhibition in order to determine the 
total effect on COX-2 activity by the H. procumbens 
extract which will be a combination of direct and indirect 
enzyme activity inhibition. 
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